Circular Genomics Strengthens Leadership Team with Key Commercial and Research Hires
New appointments hired in preparation for the launch of the world's first circular RNA-based clinical prediction test for antidepressant therapies.
"I am delighted to welcome both Dave and Vishi to our leadership team at Circular Genomics," said Dr.
Karlander brings more than 25 years of experience in the healthcare and oncology sectors, with a proven track record of leadership in the management and commercialization of diagnostics, medical devices, and pharmaceuticals. He most recently served as Senior Vice President of Commercial Operations at Biocept, where he led client services, sales, managed care, and marketing strategies for cutting-edge diagnostic technologies. Over the past decade, he has held pivotal executive positions in precision medicine at Exact Sciences, Mission Bio, and Novartis' Genoptix Medical Lab. Karlander holds an MBA from Northwestern University's Kellogg Graduate School of Management and a Bachelor of Science degree from Miami University.
About Circular Genomics
Circular Genomics is the world-leading developer of circular RNA-based precision medicine tools, data and diagnostics for psychiatry and neurology. Leveraging exclusive licenses and pioneering technologies in circular RNA, we are reshaping the standard of care for major depressive disorder and other neurological diseases. Initial products include assays to assess and tailor optimal treatment protocols for individual patients, validating treatment effectiveness within days to weeks rather than months. For additional details, please visit www.circulargenomics.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/circular-genomics-strengthens-leadership-team-with-key-commercial-and-research-hires-302071145.html
SOURCE Circular Genomics
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Katten Expands Restructuring Practice with Addition of Genevieve Weiner
- Banco Macro Announces Results for the Second Quarter of 2026
- Ingenia Therapeutics Nominated for Both the Prix Galien USA and the Inaugural Prix Galien Korea for Best Startup
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Genoptix/NovartisSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share